Abstract
Boston Scientific will report quarterly results on July 29, 2026 Pre-MKt; current expectations point to revenue of 5.36 billion US dollars and adjusted EPS of $0.83, with investors focused on Cardiovascular execution, margin resilience, and any updates around WATCHMAN and electrophysiology performance.Market Forecast
Consensus for the upcoming print implies revenue of 5.36 billion US dollars, EBIT of 1.50 billion US dollars, and adjusted EPS of $0.83, representing year-over-year growth of 9.63%, 11.70%, and 14.13% respectively. The estimates imply continued operating leverage as sales scale, consistent with a balanced expansion in profit metrics relative to top-line growth.Within the commercial mix, Cardiovascular and MedSurg remain the core engines. The most promising demand pockets cited by market commentary revolve around the left atrial appendage closure franchise (WATCHMAN) and electrophysiology, which together anchor the Cardiovascular segment’s momentum; analysts anticipate sustained positive growth trends, although segment-level consensus revenue and YoY figures for the quarter are not formally published.
Last Quarter Review
In the prior quarter, Boston Scientific delivered revenue of 5.20 billion US dollars (up 11.58% year over year), a gross profit margin of 69.21%, GAAP net profit attributable to shareholders of 1.34 billion US dollars, a net profit margin of 25.77%, and adjusted EPS of $0.80 (up 6.67% year over year). EBIT reached 1.46 billion US dollars (up 8.07% year over year), confirming solid operating execution and expense discipline.A key financial highlight was the step-up in GAAP profitability, with net profit improving sequentially by 99.55% quarter over quarter, indicating favorable operating mix and below-the-line dynamics that reinforced earnings power. In terms of business mix, Cardiovascular contributed 3.50 billion US dollars and MedSurg 1.70 billion US dollars, with Cardiovascular representing roughly 67.33% of the company total; these two pillars collectively supported the company’s 11.58% revenue growth in the quarter.
Current Quarter Outlook
Cardiovascular execution
Consensus implies that Cardiovascular continues to be the center of gravity for the quarter, with the prior quarter’s 3.50 billion US dollars revenue base setting a high bar for incremental growth. Sell-side previews emphasize steady procedure volumes and ongoing adoption in key cardiac therapies, suggesting revenue quality driven by recurring utilization and installed-base expansion. Operating leverage in this franchise is expected to support EBIT growth, given the historically favorable mix and scale benefits observed as volumes grow.The margin narrative this quarter will be shaped by pricing discipline, procedural throughput, and product mix within the portfolio. With no formal consensus gross-margin figure published for the period, investors will infer margin directionality from EBIT growth outpacing revenue growth in the estimates, a pattern that often signals healthy contribution margins and disciplined operating expense trends. Management’s ability to steer mix toward higher-value therapies, while maintaining supply reliability and field execution, will likely be interpreted as a key determinant of both operating profit delivery and guidance tone.
From a commercial standpoint, any commentary indicating sustained utilization in flagship therapies and consistent conversion of the pipeline into steady commercial demand would support the revenue consensus. If the company evidences execution that leans toward the higher end of internal goals, the market may begin to price a more robust second-half trajectory, with potential upside to EBIT if cost efficiencies continue to accrue. Conversely, any signs of slower hospital purchasing patterns or uneven demand in specific therapy lines could introduce volatility, even if the consolidated revenue result is within the expected range.
Electrophysiology and WATCHMAN trajectory
Electrophysiology and WATCHMAN are central to the quarter’s qualitative debate. Earlier this year, investor scrutiny intensified after a period when electrophysiology revenue fell short of Street expectations and U.S. WATCHMAN demand modestly undershot consensus, prompting a sharp single-day share reaction. Despite that, subsequent commentary highlighted strong organic growth in electrophysiology in the comparable quarter of the prior cycle and reiterated ambitions to outpace market expansion over the year, framing a recovery narrative that investors will evaluate against current-quarter execution.Consensus previews this quarter point to continued revenue and earnings growth for the company overall, with analysts watching for signs that WATCHMAN’s growth is normalizing upward in the U.S. and that electrophysiology utilization remains resilient across customer sites. Multiple brokers have acknowledged near-term headwinds—some cutting price targets—but maintained positive ratings, indicating that they view the setback as cyclical rather than structural. This quarter’s report will serve as a checkpoint on clinical adoption curves, competitive dynamics at the account level, and any operational learnings that can support steadier throughput.
On the revenue side, segment-level consensus figures for the quarter are not widely published, but qualitative previews expect these businesses to contribute meaningfully to aggregate growth while management calibrates channel execution and training to support consistent procedure performance. If the company evidences stable or improving demand across WATCHMAN implants and sustained electrophysiology pull-through, investors may raise confidence in second-half pacing. On the other hand, if U.S. demand indicators point to lingering softness or if the cadence of new account ramping slows, near-term sentiment could remain sensitive even if consolidated results meet guidance.
What may move the stock on July 29, 2026
The most direct catalysts are revenue versus consensus, adjusted EPS delivery, and the tone of management’s intra-quarter commentary on order flow and product uptake, especially across WATCHMAN and electrophysiology. Since formal gross-margin estimates are not broadly published for this quarter, investors will triangulate profitability from EBIT and EPS versus revenue; a beat on EBIT accompanied by stable operating expense intensity would be viewed as favorable margin execution. The net read-through for valuation will also depend on whether management provides color that supports the durability of double-digit revenue growth into the back half.Recent broker actions show a cluster of price-target reductions while ratings remain positive. That sets a bar that is achievable if execution lands in-line and the outlook comments reduce perceived volatility tied to product-specific headlines earlier in the year. The shares have already absorbed an extended period of estimate recalibration, including concern around an FDA-related recall and selective pressure on growth expectations, so better-than-feared commentary on product availability, field performance, and account activity would carry outsized influence on post-earnings trading.
Investors will also parse any updates related to capital deployment and portfolio initiatives mentioned in recent research notes, including longer-term optionality around structural heart. One preview highlighted potential upside associated with MiRus over time, while others emphasized continued buy-rated stances predicated on diversified growth. Though these are not immediate-quarter revenue drivers, the framing of pipeline and portfolio-level execution often informs how the market discounts future growth beyond the current year. A clear articulation of commercial milestones and regulatory timelines will help the market assess the durability of multi-year growth without requiring near-term estimate revisions.
Analyst Opinions
Across the review period, published rating actions are overwhelmingly supportive: the ratio of bullish to bearish opinions is approximately 100% to 0% among at least ten prominent broker notes. Multiple firms reiterated Buy or Outperform ratings while cutting price targets to reflect recalibrated near-term risk-reward. Jefferies reaffirmed a Buy with updated targets in the mid-to-high $60s in recent weeks, while also appearing in earlier notes with triple-digit targets tied to longer-term growth. Wells Fargo maintained a Buy with a 75-dollar target, citing continued confidence in the company’s growth engines even as the market absorbed a series of headline pressures.J.P. Morgan remained constructive, with Robbie Marcus maintaining a Buy stance and indicating that near-term WATCHMAN headwinds have not undermined the longer-term growth profile. Citi’s Joanne Wuensch kept a Buy rating and a 70-dollar target, emphasizing the path to sustained growth as product execution stabilizes. Bank of America’s Travis Steed reiterated a Buy with a 68-dollar target, underscoring the belief that recent softness in specific areas can be managed within the broader growth plan. Needham’s Michael Matson retained Buy while adjusting the target to 57 dollars, and Evercore ISI and BTIG updated targets to the mid-60s range while preserving Buy ratings.
Goldman Sachs maintained Buy in more than one note during the period as targets were recalibrated, reinforcing the narrative that the investment case remains intact despite shorter-term volatility. Piper Sandler trimmed the target to 65 dollars but kept a positive rating, and RBC reiterated that the company’s 2026 growth framework remains intact despite WATCHMAN pressures earlier in the year. TD Cowen’s Josh Jennings also reaffirmed Buy, describing resilient fundamentals and diversified growth that support the earnings outlook.
The majority view coalesces around a constructive stance heading into the July 29, 2026 report: consensus expects revenue of 5.36 billion US dollars and adjusted EPS of $0.83, and the core debate centers on whether WATCHMAN and electrophysiology trends are stabilizing and whether operating leverage can be preserved. With a cluster of Buy ratings—even after target reductions—the prevailing expectation is that the quarter will show continued progress in revenue and profit metrics and that management commentary will be crucial for shaping second-half conviction. Analysts indicate that clear evidence of steady procedural demand, disciplined cost control, and supportive product-mix trends would validate the thesis that earnings growth can remain ahead of revenue growth, which is embedded in the 14.13% year-over-year EPS estimate versus 9.63% revenue growth.
Comments